Active — Not RecruitingPhase 2

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

United States24 participantsStarted 2018-12-31

Plain-language summary

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Patients with active graft-versus-host-disease are not eligible
✕. Patients receiving immunosuppressive therapy for prevention of graft-versus-host disease are not eligible

overall response rate of CPI-613

Timeframe: 3 years

NCT IDNCT03793140

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12